Virginia Foreste

Virginia Foreste

Auto-generated profile, based on publicly available information

Virginia Foreste

Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PGPierluigi Giampaolino
Pierluigi Giampaolino
VFVirginia Foreste
Virginia Foreste
CFClaudia Di Filippo
Claudia Di Filippo
AGAlessandra Gallo
Alessandra Gallo
Antonio MercorioAntonio Mercorio
Antonio Mercorio
Luigi Della CorteLuigi Della Corte
Luigi Della Corte
Polycystic ovary syndrome (PCOS) is a complex and heterogeneous endocrine disease. The hypothesis that alterations in the microbiome are involved in the genesis of PCOS has been postulated. Aim of this review is to summarize the available literature data about the relationship between microbiome and PCOS. A search on PubMed and Medline databases was performed from inception to November 20Most of evidence has focused on the connection of intestinal bacteria with sex hormones and insulin-resistance: while in the first case, a relationship with hyperandrogenism has been described, although it is still unclear, in the second one, chronic low-grade inflammation by activating the immune system, with increased production of proinflammatory cytokines which interfere with insulin receptor function, causing IR (Insulin Resistance)/hyperinsulinemia has been described, as well as the role of gastrointestinal hormones like Ghrelin and peptide YY (PYY), bile acids, interleukin-22 and Bacteroides vulgatus have been highlighted. The lower genital tract microbiome would be affected by changes in PCOS patients too. The therapeutic opportunities include probiotic, prebiotics and synbiotics, as well as fecal microbiota transplantation and the use of IL-22, to date only in animal models, as a possible future drug. Current evidence has shown the involvement of the gut microbiome in PCOS, seen how humanized mice receiving a fecal transplant from women with PCOS develop ovarian dysfunction, immune changes and insulin resistance and how it is capable of disrupting the secondary bile acid biosynthesis. A future therapeutic approach for PCOS may involve the human administration of IL-22 and bile acid glycodeoxycholic acid.

1 August 2020 in Gland Surgery
Verified
Journal Article
Open access
PDF file
PGPierluigi Giampaolino
Pierluigi Giampaolino
VFVirginia Foreste
Virginia Foreste
LCLuigi Della Corte
Luigi Della Corte
CFClaudia Di Filippo
Claudia Di Filippo
GIGiuseppe Gabriele Iorio
Giuseppe Gabriele Iorio
GBGiuseppe Bifulco
Giuseppe Bifulco
Ovarian cancer is frequently diagnosed at an advanced stage and a fraction of these patients fail to respond to primary therapy and relapses in 70% of cases. On account of the high recurrence probability and the poor outcomes after recurrence, there is an urgent need to predict progression as early as possible and thus found the strategies to detect and prevent a recurrence. Considering that biomarkers have contributed to the management of ovarian cancer by distinguishing benign and malignant pelvic masses and monitoring response to treatment, in this review, we aim to discuss the latest evidence reported in the literature about the use of biomarkers to detect OC recurrence. In detail, we summarized all the evidence of the most quoted biomarkers like HE4, osteopontin, mesothelin (MSLN), Folate receptor α (FOLR1), paraneoplastic antigens, miRNA, cancer stem cells (CSCs) and a combination of them to evaluate their role as prognostic biomarkers for ovarian cancer recurrence.

27 June 2020 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
Luigi Della CorteLuigi Della Corte
Luigi Della Corte
VFVirginia Foreste
Virginia Foreste
Fabio BarraFabio Barra
Fabio Barra
CGClaudio Gustavino
Claudio Gustavino
FAFranco Alessandri
Franco Alessandri
PGPierluigi Giampaolino
Pierluigi Giampaolino
Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects 8–13% of reproductive-age women. Irregular periods, hirsutism, or infertility are the most common clinical presentations of pa...

8 February 2020 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
Luigi Della CorteLuigi Della Corte
Luigi Della Corte
Fabio BarraFabio Barra
Fabio Barra
VFVirginia Foreste
Virginia Foreste
PGPierluigi Giampaolino
Pierluigi Giampaolino
GEGiulio Evangelisti
Giulio Evangelisti
GBGiuseppe Bifulco
Giuseppe Bifulco
Introduction: Cervical cancer is the fourth common cancer in women worldwide. While, in the past, locally advanced stage disease was treated by pelvic radiotherapy, nowadays the National Cancer Institute strongly recommends chemoradiation protocols. Weekly cisplatin was previously the standard of care in this setting; however, the low response rate and the short median progression-free survival (PFS) of patients have led researchers to investigate combinatory regimens. Area covered: This article is based on literature searches up until April 2019, with current trial registers also analyzed. All data available on this topic has been summarized in this narrative review. Expert opinion: In recent years, it has been demonstrated that cisplatin-based doublets, and in particular, cisplatin plus paclitaxel, are superior to cisplatin as a monotherapy in terms of response rate and progression-free survival of patients with advanced cervical cancer. This double regime combined with bevacizumab is also considered the first-line option for metastatic or recurrent disease. Dose-dense paclitaxel in neo-adjuvant chemotherapy combinations is a promising option in patients with locally advanced cervical cancer. Exploration of novel biological therapies and in vitro combinations based on the use of paclitaxel is warranted.

10 May 2020 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
PDF file
Fabio BarraFabio Barra
Fabio Barra
Luigi Della CorteLuigi Della Corte
Luigi Della Corte
GNGiovanni Noberasco
Giovanni Noberasco
VFVirginia Foreste
Virginia Foreste
GRGaetano Riemma
Gaetano Riemma
SFSimone Ferrero
Simone Ferrero

1 July 2019 in Minerva Medica
Verified
Journal Article
Closed access
PGPierluigi Giampaolino
Pierluigi Giampaolino
LCLuigi Della Corte
Luigi Della Corte
VFVirginia Foreste
Virginia Foreste
Salvatore Giovanni VitaleSalvatore Giovanni Vitale
Salvatore Giovanni Vitale
Benito ChiofaloBenito Chiofalo
Benito Chiofalo
GBGiuseppe Bifulco
Giuseppe Bifulco
Epithelial ovarian cancer (EOC) is the predominant type of ovarian cancer (OC). The 5-year survival of patients has improved over the last three decades, although the overall cure rate of OC if about 30%. Despite high response rates after initial chemotherapy, most patients with advanced ovarian cancer ultimately develop the recurrent disease because of resistance to chemotherapy. A proper early diagnosis and treatment of patients with ovarian cancer are urgently needed. Nowadays the diagnosis is performed by means of clinical symptoms and signs, often indicators of a disease already at an advanced stage, tumor markers (CA125 and HE4), transvaginal ultrasonography and imaging, very useful in distinguishing adnexal masses. Understand the nature of an adnexal mass is the primary point to begin the diagnosis of OC. Validated different model to approach and characterize adnexal pathology preoperatively are described, such as the International Ovarian Tumor Analysis (IOTA) and the Assessment of Different NEoplasias in the AdneXa (ADNEX) model. New tumor markers, such as PRSS8, FOLR1, KLK6/7, GSTT1, and miRNAs, are getting ahead and are worth noting for early detection of ovarian cancer. Despite the development of numerous ultrasound models for the diagnosis of adnexal masses and the analysis of different tumor markers, the early diagnosis of ovarian cancer is still difficult to practice. Moreover, identifying genetic risk alleles, such as germline BRCA1 and BRCA2 mutations, for ovarian cancer has had a significant impact on disease prevention strategies.